Efficacy, safety, and tolerability of pravastatin for the long-term treatment of patients with diverse types of hyperlipidemia: A multicenter prospective study

O'Malley, 1990, The influence of apolipoprotein E phenotype on the response to lovastatin therapy in patients with heterozygous familial hypercholesterolemia, Metabolism, 39, 150, 10.1016/0026-0495(90)90068-N

Mol, 1988, Simvastatin (MK733): A potent cholesterol synthesis inhibitor in heterozygous familial hypercholesterolemia, Atherosclerosis, 69, 131, 10.1016/0021-9150(88)90006-8

Franceschini, 1989, Plasma lipoprotein changes after treatment with pravastatin and gemfibrozil in patients with familial hypercholesterolemia, J Lab Clin Med, 318, 250

Havel, 1987, Lovastatin in the treatment of heterozygous familial hypercholesterolemia: A multicenter study, Ann Intern Med, 107, 609, 10.7326/0003-4819-107-5-609

Illingworth, 1987, Hypolipidemic effects of HMG-CoA reductase inhibitors in patients with hypercholesterolemia, Am J Cardiol, 60, 33G, 10.1016/0002-9149(87)90589-3

Illingworth, 1989, Treatment of heterozygous familial hypercholesterolemia with lipid lowering drugs, Arteriosclerosis, 9, 121

Friedwald, 1972, Estimation of the concentration of low density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge, Clin Chem, 18, 499, 10.1093/clinchem/18.6.499

Consensus Conference, 1985, Lowering blood cholesterol to prevent coronary heart diseae, JAMA, 253, 2080, 10.1001/jama.1985.03350380096029

1987, Strategies for the prevention of coronary heart disease: A policy statement of the European Atherosclerosis Society, Eur Heart J, 8, 77

Lipid Research Clinics Program, 1984, The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease, JAMA, 251, 351, 10.1001/jama.1984.03340270029025

Nakaya, 1987, The side effect of CS-514 on serum lipids and apoproteins in hypercholesterolemic subjects, JAMA, 257, 3088, 10.1001/jama.1987.03390220086026

Mantell, 1989, Lipid lowering drugs in atherosclerosis: The HMG CoA reductase inhibitor, Clin Exp Hypertens, 6, 927, 10.3109/10641968909035383

Raasch, 1991, Pravastatin sodium, a new HMG-CoA reductase inhibitor, Ann Pharmacother, 25, 388

Ojala, 1990, Long-term maintenance of therapeutic response to lovastatin in patients with familial and non-familial hypercholesterolemia: A 3-year follow-up, Atherosclerosis, 82, 85, 10.1016/0021-9150(90)90147-B

Grundy, 1988, HMG-CoA reductase inhibitors for treatment of hypercholesterolemia, N Engl J Med, 319, 24, 10.1056/NEJM198807073190105